AVROBIO Inc

NASDAQ AVRO

Download Data

AVROBIO Inc Liabilities to Equity Ratio 5 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: -12.42%

AVROBIO Inc Liabilities to Equity Ratio 5 year CAGR is -12.42% for the Trailing 12 Months (TTM) ending March 31, 2024. The liabilities to equity ratio, also known as the leverage ratio, measures the proportion of a company's total liabilities to its shareholders' equity. It is calculated by dividing the total liabilities by the shareholders' equity. This ratio provides insights into the extent to which a company relies on debt financing compared to equity financing. A higher ratio indicates higher financial leverage, which can amplify both returns and risks for the company's shareholders. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • AVROBIO Inc Liabilities to Equity Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.38, a 140.93% change year over year.
  • AVROBIO Inc Liabilities to Equity Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.16, a 100.97% change year over year.
  • AVROBIO Inc Liabilities to Equity Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.08, a 10.37% change year over year.
  • AVROBIO Inc Liabilities to Equity Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was 0.07, a -8.39% change year over year.
NASDAQ: AVRO

AVROBIO Inc

CEO Mr. Geoff MacKay BSc
IPO Date June 21, 2018
Location United States
Headquarters Building 300, Cambridge, MA, United States, 02139
Employees 13
Sector Healthcare
Industry Biotechnology
Description

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Similar companies

HEPA

Hepion Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email